Announcement

Cytiva and Culture Biosciences expand strategic collaboration

Culture Biosciences, an expert in cloud-connected bioreactor technology, and Cytiva, a Danaher company and a leader in the life sciences industry, have expanded their strategic collaboration to include both hardware commercialization and technology development.

Building on an existing collaboration to offer a Cytiva 250mL consumable featuring a scaled-down version of its Xcellerex X-Platform technology for use with Culture’s Stratyx 250 system, the expanded relationship will now include global commercialization by Cytiva of Culture’s Stratyx 250 hardware and joint development of additional bioreactor formats. 

Chris Williams, CEO, Culture Biosciences, says: “By aligning our innovative bioreactor technology with Cytiva’s global reach and leadership in bioprocessing, we are accelerating the future of digital bioprocessing.”

Cytiva will serve as the exclusive global distributor of Culture’s Stratyx 250 bioreactor platform and associated consumables. Cytiva’s global infrastructure and customer reach will help ensure broad access to this next-generation, small-scale bioprocessing technology. The companies will collaborate to expand the Stratyx product line. This expanded portfolio will feature consumables built with Cytiva’s Xcellerex X-Platform technology, enabling seamless scale-up from 250 mL to 2,000 liters—offering customers an integrated and scalable solution across their bioprocessing workflows.

Jon Van Pelt, Vice President and General Manager, Single Use Technologies, Cytiva, says: “Expanding our collaboration with Culture Biosciences will help us deliver smarter, scalable, and connected biomanufacturing systems for our customers.”

By combining Culture’s expertise in cloud-enabled, small-scale bioreactors with Cytiva’s global scale and bioprocessing leadership, the companies are poised to deliver a fully integrated solution—from benchtop to production scale—that empowers biopharma innovators to accelerate development timelines, improve data connectivity, and scale processes with confidence. 

Xcellerex, Cytiva and the drop logo are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.

About Culture Biosciences 

Culture is on a mission to revolutionize bioprocess development with a powerful combination of hardware and cloud-native software—that makes data accessible, contextualized, and actionable—unlocking the full potential of end-to-end bioprocessing capabilities.

About Cytiva

At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15,000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers.  Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at Cytiva.com

Cytiva is proud to be part of Danaher. Visit www.Danaher.com to learn more about Danaher, a leading life sciences and diagnostics innovator committed to accelerating the power of science and technology to improve human health.

Media Contact

Lauren Kellogg, lauren@culturebiosciences.com

Keep exploring

Announcement

Culture Biosciences unveils Stratyx™ 250, the first cloud-integrated, mobile bioreactor for cell culture process development

April 1, 2025
Announcement

Culture Biosciences Joins Forces with Ginkgo Technology Network Partner

February 28, 2024